Description

Hundreds of breakthrough treatments are transforming patients’ lives in the US — but still aren’t available in Europe.

In this short extract, Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio, reveals the shocking scale of this innovation gap… and why it’s growing.

The full episode drops tomorrow on Pharma minds — don’t miss it!

What you will learn in the full episode of tomorrow :

◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.

◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.

◾️ The consequences for patients, innovation, and the competitiveness of Europe’s healthcare ecosystem.

◾️ Pierre-Henri’s proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.

◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.

A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.

See you tomorrow!

---

🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.

🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.

📩 Curious to dive deeper into the major shifts in the pharma and healthcare ecosystem? Subscribe to the Pharma Minds newsletter.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Transcription

• Speaker #0

  Hello everyone and welcome to PharmaMinds, the podcast that takes you behind the scenes with the leading figures in the pharma world. New week, new episode, and here's a sneak peek of the conversation you can catch online starting tomorrow.

• Speaker #1

  There are hundreds and if not thousands of new molecular entities, so new drugs that are phase 2 plus and are not partners. And we see this big wave of innovation, which is absolutely great news for patients. It's getting through a lot of disease with no treatment at the moment, a lot of often a lot of neglected diseases. And when you look at the statistics, and it's not my statistics, it's QVR statistics, there are more than 100 drugs that have been launched in the US in the last five years that are not in Europe, right? And we see this number is very constantly growing. Unfortunately, and it means just it's as simple as that, is that patients in Europe are not treated the same way as in the US and have not access to the same type of drug rights. And here we're really talking about new molecular entities. So not even, you know, similar or generics or things like that.

• Speaker #0

  If you enjoyed this snippet, remember to subscribe on this app and turn on the notifications to be the first to know when the full episode is out. Wishing you a fantastic listening experience and I'll see you soon on PharmaMinds.